Short answer
Editas Medicine, Inc. (EDIT) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers). Q2 2026 financial results covered quarter ended June 30, 2026.
Editas Medicine, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results covered quarter ended June 30, 2026
- Press release includes business highlights and detailed results in Exhibit 99.1
- Filing date August 5, 2026; investor focus on cash runway and clinical progress in accompanying release
Item 5.02 · Departure/Election of Directors or Officers
- Elliott Levy resigned as class I director effective August 4, 2026, without disagreement with Editas Medicine
- Patrick Ellinor appointed independent class I director effective August 6, 2026
- Ellinor brings senior cardiovascular leadership from Mass General Brigham, Harvard Medical School, and Broad Institute
- Annual board cash compensation of $40,000 plus option for 103,400 shares
- Option vests in three equal installments over three anniversaries, with exercise price set at appointment-date closing price
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Editas Medicine, Inc. 8-K filings
Get the next EDIT 8-K as it lands
Follow EDIT for push alerts, or ask the research agent what this filing means.